Evaluation of Checkpoint Inhibitors on Tumor Infiltrating Immune Cells in the Orthotopic and Metastatic Tumor Microenvironment using Bioluminescent Syngeneic Cell Line Models
Andrew McKenzie, Nektaria Papadopoulou, Simon Jiang, Jane Wrigley, Sumanjeet Malhi, Jason King, Kelly Jones, Russell Garland*, Neil Williams*, and Rajendra Kumari
*KWS BioTest, Bristol, UK
Subcutaneous syngeneic models are widely used to evaluate the impact of immunotherapy on tumor growth and tumor invading leukocytes (TILs).
However, the tumor microenvironment of orthotopic models is more patient-relevant with an organ-specific site, facilitation of metastatic spread and, for syngeneic models, supporting immune and stromal component interactions.
CrownBio has developed bioluminescent variants of syngeneic cell lines to assess the impact of orthotopic growth on response to immune checkpoint therapy.
Read this Poster to Discover:
- How BLI enables non-invasive longitudinal monitoring of orthotopic/metastatic tumor burden, allowing for optimal randomization, reduction of false positives, and continuous feedback supporting optimal treatment regimen mid-study
- Immune checkpoint inhibitor and TIL studies with bioluminescent breast, hepatoma, melanoma, and pancreatic syngeneic models
- A panel of bioluminescent mouse cell lines, amenable to the development of orthotopic and metastatic models for further exploring strategies involving immunotherapy